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Background: Glioma is the most common primary malignant central nervous system tumor in adult, and is usually not
curable due to its invasive nature. Establishment of serum biomarkers for glioma would be beneficial both for early
diagnosis and adequate therapeutic intervention. Filamins are an actin cross-linker and filamin C (FLNC), normally
restricted in muscle tissues, offers many signaling molecules an essential communication fields. Recently, filamins have
been considered important for tumorigenesis in cancers.
Methods: We searched for novel glioma-associated antigens by serological identification of antigens utilizing
recombinant cDNA expression cloning (SEREX), and found FLNC as a candidate protein. Tissue expressions of FLNC
(both in normal and tumor tissues) were examined by immunohistochemistry and quantitative RT-PCR analyses.
Serum anti-FLNC autoantibody level was measured by ELISA in normal volunteers and in the patients with various
grade gliomas.
Results: FLNC was expressed in glioma tissues and its level got higher as tumor grade advanced. Anti-FLNC autoantibody
was also detected in the serum of glioma patients, but its levels were inversely correlated with the tissue expression.
Serum anti-FLNC autoantibody level was significantly higher in low-grade glioma patients than in high-grade glioma
patients or in normal volunteers, which was confirmed in an independent validation set of patients’ sera. The
autoantibody levels in the patients with meningioma or cerebral infarction were at the same level of normal
volunteers, and they were significantly lower than that of low-grade gliomas. Total IgG and anti-glutatione
S-transferase (GST) antibody level were not altered among the patient groups, which suggest that the autoantibody
response was specific for FLNC.
Conclusions: The present results suggest that serum anti-FLNC autoantibody can be a potential serum biomarker for
early diagnosis of low-grade gliomas while it needs a large-scale clinical study.
Keywords: Glioma, Filamin C, FLNC, Biomarker, Early diagnosisBackground
Glioma is the most common type of primary brain tumor
in adults. Currently, tumor grading by histological analysis
of surgically-resected specimens is the most reliable pre-
dictor of glioma prognosis. They are classified into four
grades; low-grades including WHO Grade I (localized gli-
omas) and WHO Grade II (diffuse gliomas), and high-
grades including WHO Grades III (anaplastic gliomas)
and WHO Grade IV (glioblastoma). Despite the recent* Correspondence: iwadatey@faculty.chiba-u.jp
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article, unless otherwise stated.advances in glioma diagnosis and therapy, two-year sur-
vival for the grade IV glioblastoma is less than 30%. Even
among patients with low-grade gliomas that usually confer
a relatively good prognosis, treatment is almost never
curative under the current diagnostic system [1].
Identification of specific glioma antigens is long awaited
for the clinical management such as early diagnosis, more
objective diagnosis, monitoring treatment response, and
for novel therapeutic targets for glioma [2-5]. In the previ-
ous study utilizing proteomics, we found several proteins
that are overexpressed in high-grade gliomas and some
were potentially applicable to serum biomarkers by ability
of secretion [6]. Serum levels of these candidate proteinsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characteristics of the training set and validation
set










Mean 46.6 47.6 49.2 51.2
Range 12-74 34-68 24-78 22-77
Sex
Male 40 21 37 21
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vasive nature of the tumor and patient survival periods [7,8].
However, detection of low-grade tumors is difficult by utiliz-
ing the protein amount-based diagnostic system because
their serum protein levels may not be sufficiently altered to
be detectable by current proteomic technologies. One ap-
proach for overcoming this difficulty and thereby enable
early detection of slight changes in protein amount, protein
structure or protein localization would be utilization of
antigen-antibody interactions [9,10]. Detection of the host
immune reactions which can respond to slight changes in
the precursor cells that have started to transform into neo-
plastic cells would be a breakthrough to enable early diagno-
sis of cancers including glioma. To verify this concept, we
utilized immunoscreening of cDNA libraries prepared from
glioblastoma cells with IgG in the sera from glioma patients.
We found filamin C (FLNC), which is normally restricted
in muscle tissues but abundantly exists in fetal central ner-
vous system [11,12], as a candidate protein for glioma anti-
gen. Filamins are an actin cross-linker, and serve as
scaffolds for many binding partners including channels, re-
ceptors, intracellular signaling molecules, and transcription
factors [13,14]. Because of these extensive fields of associat-
ing proteins, mutations in filamin genes result in a wide
range of cell and tissue anomalies. Especially they have a
decisive role in cellular motility and migration [11-14]. Fur-
thermore, Filamin genes mutations are common in human
breast and colon cancers [15]. Many recent studies have
suggested filamin A as an important factor for tumor ma-
lignancy and invasiveness in various human cancers in-
cluding primary brain tumors [16-20]. In addition, filamin
A interacts with BRCA1/2 or other DNA repair-related
proteins to affect the DNA repair process resulting in re-
sistance to radiation and chemotherapy [21,22]. In this
paper, we examined tissue expressions of FLNC (both in
normal and tumor tissues), and investigated the serum
levels of anti-FLNC autoantibody in glioma patients.
Methods
Sera and tissue specimens
We analyzed 131 glioma patients’ sera (low-grade, 72; high-
grade, 59) along with 77 sera from healthy volunteers, 19
sera from patients with meningioma, and 24 patients with
cerebral infarction at chronic stage. These were newly-
diagnosed patients, and had no other cancer or diseases at
the time of sample collection. They had serum drawn at
the time of initial diagnosis. The patient demographics and
clinical profiles are presented in Table 1. Forty-eight glioma
tissues surgically-resected from newly diagnosed glioma pa-
tients (low-grade, 22; high-grade, 26) and 10 healthy brain
tissues were analyzed for the tissue expression of FLNC.
The normal brain tissues were obtained from the patients
undergoing resection of extra-axial brain tumors or epilepsy
surgery. Sixty-five serum samples from glioma patients and38 samples from healthy volunteers were used to develop a
diagnostic model (training set) that was validated in an inde-
pendent, blinded validation set using the serum samples from
66 glioma patients and 39 healthy volunteers. The protocol
of this study was approved by the Institutional Review Board
of Chiba University, and written informed consent was ob-
tained from the patients or their guardians. Total RNAs of
the lung, liver, spleen, testis and muscle were commercially
obtained (Zyagen Laboratories, San Diego, CA). Total RNAs
of lung, liver, spleen, testis and muscle were commercially ob-
tained (Zyagen Laboratories, San Diego, CA).
Serological analysis of recombinant cDNA expression
libraries (SEREX)
Total RNA was prepared from the U87MG glioblastoma cell
line by the acid guanidium thiocyanate-phenol-chloroform
method, and purified to poly(A) + RNA using the Oligotex-
dT30 (Super) mRNA Purification Kit (Takara Biochemicals,
Kyoto, Japan). cDNA was ligated into the EcoRI-XhoI site of
the λZAP II phage. The original library size was 1 × 106.
Escherichia coli XL1-Blue MRF’ was infected with the λZAP
II phages which contained the U87MG cDNA library, and
the expression of cDNA was induced by blotting on nitro-
cellulose membranes which had been pretreated for
30 min with 10 mM IPTG (Wako Pure Chemicals, Osaka,
Japan). After washing and blocking, the membranes were
exposed in 1:2000-diluted sera from 18 glioma patients.
Then, the membranes were treated with 1:5000-diluted al-
kaline phosphatase-conjugated F(ab)’ fragment-specific
goat antihuman IgG. Positive reactions were detected by
incubation in a color development solution containing
0.3 mg/mL of nitroblue tetrazolium chloride and 0.15 mg/
mL of 5-bromo-4-chloro-3-indolyl-phosphate. Positive
clones were re-cloned twice to obtain monoclonality and
retested for the serum reactivity.
Adachi-Hayama et al. BMC Cancer 2014, 14:452 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/452Sequence analysis of identified antigens
Monoclonalized phage cDNA clones were converted to
pBluescript phagemids by in vivo excisions with ExAssist
helper phage (Stratagene, La Jolla, CA). Plasmid DNA was
obtained from E. coli SOLR strain transformed by the pha-
gemid. The cDNA inserts were sequenced by the dideoxy
chain termination method using the DNA sequencing kit
BigDye Terminator (Applied Biosystems, Foster City, CA).
Sequences were analyzed for homology with public data-
bases of known genes and proteins using BLAST on the
National Center for Biotechnology Information’s website
(http://www.ncbi.nlm.nih.gov/gene or protein).
Purification of recombinant FLNC protein
The cDNA insert of FLNC incorporated in pBlueScript
was cleaved by EcoRI and XhoI, and then recombined in
pGEX-4 T-3. E. coli JM109 cells containing either pGEX-
4 T-3- FLNC or control pGEX-4 T-3 were cultured in
200 mL of Luria broth and treated with 1 mM IPTG for
2.5 hrs. The cell lysate was centrifuged and GST-FLNC in
the supernatant was directly purified with glutathione-
Sepharose (Amersham Biosciences, Piscataway, NJ). The
purified proteins were concentrated using Apollo centrifu-
gal concentrators (Orbital Biosciences, Topsfield, MA).ELISA for anti-FLNC autoantibody
Fifty μl of antigen (GST or GST-tagged recombinant FLNC)
was added to each well, and incubated at 4°C overnight.
The plate was washed and blocked with 10% fetal calf serum
in PBS (PBS-FCS). Fifty μl of sera diluted at 1:100 in 10%
PBS-FCS was added to the wells and then they were incu-
bated. The bound IgG antibodies were detected by incubat-
ing with horseradish peroxidase-conjugated antihuman IgG
antibody (Jackson Immuno Research Laboratories, West
Grove, PA), followed by the addition of 100 μl of a peroxid-
ase substrate (o-phenylenediamine, 0.4 mg/ml) in a
citrate-phosphate buffer. Absorbance at 490 nm was de-
termined using a microplate reader (Emax; Molecular
Devices, Sunnyvale, CA).Figure 1 Tissue expression of filamin C mRNA was measured by
quantitative real-time RT-PCR analysis in normal brain tissues,
low-grade gliomas, and high-grade gliomas, and also in lung,
liver spleen, testis and muscle which were commercially obtained.
The filamin C mRNA expression was significantly up-regulated in
high-grade gliomas compared with normal brain tissues. It was
moderately upregulated in low-grade gliomas and normal muscle
tissues. The mean values of duplicate experiments for each sample
are presented.Sandwich ELISA for Serum FLNC measurement
ELISA 96-well plates were coated with 20 μg/ml antihu-
man FLNC antibody, and were filled overnight with 50 μl
of patients’ sera diluted 1:100. The plates were developed
with o-phenylene-diamine (Sigma-Aldrich, St Louis, MO)
and were read at an absorbance of 490 nm.
Total IgG measurement
Serum total IgG was measured in the same samples as the
anti-FLNC autoantibody measurements according to the
manufacturer’s instructions using a human IgG ELISA
quantitative kit (Bethyl, Montgomery, TX).Extraction of mRNA and preparation of cDNA
The mRNAs were extracted from the tumors and nor-
mal brain tissues using the QIAzol Lysis Reagent and
RNeasy® Lipid Tissue Mini Kit (QIAGEN, Tokyo, Japan),
followed by DNase treatment. One μg of each mRNA
was reversely transcribed using the oligo dT primer
(Takara Biochemicals, Inc., Tokyo, Japan) and Super
Script II (Invitrogen, CA).
Real-time RT-PCR
The real-time quantitative RT-PCR with SYBR-green was
performed using the Light Cycler (Roche Diagnostics,
Meylan, France). The amplification was performed using
5’-GGACATGAGTGGCCGGTACAC-3’ as the forward
primer and 5’-ACTGTGACGAGGCACTTGCTG-3’ as
the reverse primer. A series of cDNA dilutions, 1/1, 1/10,
1/100, and 1/1000, were used in each run separately.
Standard curves were obtained by doing serial dilutions of
the same sample in each run. Then, 1 mM of each primer
and 3 mM of MgCl2 in the total volume of 20 μl were
used. The real-time RT-PCR cycle started with the initial
denaturation at 95°C for 10 min, followed by 45 cycles of
denaturation at 95°C for 10s, annealing at 61°C for 10s
and then elongation at 72°C for 10s. As an internal quanti-
tative control of the gene expression, the glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) gene expression
was used. The ratios of filamin C and GAPDH gene
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filamin C expressions.
Immunohistochemistry
IHC staining was performed on 4 μm paraffin-embedded
sections. Antigenicity was recovered by the microwave
method. Endogenic peroxidase was inactivated with 0.3%
H2O2 methanol. After antigen blocking, the sections were
incubated overnight with mouse monoclonal primary anti-
body against FLNC (Lab Vision, Fremont, CA). The sec-
tions were then incubated with mouse biotinylated













Figure 2 Immunohistochemistry (IHC) for FLNC among normal brain,
expression level was higher in high-grade glioma (e, f) than in low-grade g
normal brain tissues (a, b). FLNC expression is only observed around the n
cytoplasm and the fibrous cellular processes of the glioma cells (magnifica
shows that the mean percentage of positive tumor cells gets higher as the
low-grade glioma vs high-grade glioma; p = 0.0005).Finally, the reaction was visualized using DAB and counter-
stained with hematoxylin. To quantitate FLNC protein ex-
pression, the mean percentage of positive tumor cells was
determined in at least 5 random fields at x400 magnifica-
tion in each section.
Statistical analysis
Results of ELISA were statistically analyzed by unpaired t-
test. Receiver–operating characteristics (ROC) curve ana-
lysis was used to determine the optimal cutoff values for
differential diagnosis of low-grade gliomas and healthy vol-
unteers. The survival rates were estimated using Kaplan-low-grade glioma and high-grade glioma. (A) FLNC protein
lioma (c, d) which expressed significantly higher level of FLNC than
ucleus of glia cells in normal brains, whereas it spreads into the whole
tion × 400). (B) Quantitative analysis of FLNC protein expressions in IHC
tumor grade advances. (normal brain vs low-grade glioma; p = 0.0132,
A B
Figure 3 ELISA of anti-FLNC autoantibody levels in the sera from glioma patients and normal volunteers. (A) For a training set, anti-FLNC
autoantibody concentration in the sera from low-grade gliomas was significantly higher than those from high-grade gliomas (p = 0.0101) or
normal volunteers (p < 0.0001). (B) The ELISA result obtained in the training set was confirmed in an independent validation set (low-grade vs.
high-grade: p = 0.0036, low-grade vs. healthy: p = 0.0010).
Table 2 Sensitivity and specificity of anti-FLNC antibody




Healthy volunteers 77 0.242 0.115 __
Low-grade gliomas
Grade I 15 0.359 0.112 0.0021
Grade II 57 0.373 0.152 <0.0001
High-grade gliomas
Grade III 18 0.254 0.159 0.9748
Grade IV 41 0.268 0.101 0.7503
Meningioma 19 0.273 0.081 0.2281
Cerebral infraction 24 0.273 0.082 0.5531
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test. The correlation between the filamin C mRNA expres-
sion levels and serum anti-FLNC autoantibody concentra-
tions was analyzed using the non-parametric Spearman’s
rank test. The statistical analyses were performed using
Stat-View software and SAS software (SAS Institute Inc.,
Cary, NC).
Results
Screening of the patients’ sera by serological analysis of re-
combinant cDNA expression libraries (SEREX) resulted in
identification of filamin C (FLNC) as one of the candidate
glioma antigens (Additional file 1: Table S1). The list in-
cluded many signal-transduction molecules and transcrip-
tion factors, which was also confirmed in a previous
proteomic study.
We first examined whether the expression of filamin
C mRNA is elevated in the glioma tissues (Figure 1).
Quantitative reverse transcription–PCR (qRT-PCR)
analysis of various glioma tissues and normal brain tis-
sues confirmed that filamin C mRNA expression was
significantly up-regulated in low-grade gliomas com-
pared with normal brain tissues. High-grade gliomas
expressed higher level of filamin C mRNA than low-grade
gliomas. Other normal tissues including lung, liver, spleen,
and testis contained the same levels of filamin C mRNA
as normal brain tissues. In contrast, muscle tissues had a
higher level than the other normal tissues and the same
level as low-grade glomas (Figure 1).
We then analyzed protein expression levels and distri-
butions in paraffin-embedded clinical specimens utiliz-
ing semiquantitative immunohistochemical analysis
(Figure 2). FLNC protein expression level was higher in
high-grade glioma than in low-grade gliomas which
expressed significantly higher level of FLNC than normal
brain tissues (Figure 2-a, 2-b). FLNC protein expression
was only observable around the nucleus of glial cells innormal brain tissue, but it spread into the whole cyto-
plasm and the fibrous cellular processes in the low-grade
glioma cells (Figure 2-c).
We measured anti-FLNC auto-antibody concentrations
by ELISA in a training set consisting of 65 glioma patients
(low-grade, 35; high-grade, 30) and 38 healthy volunteers
focusing on FLNC (Table 1). The results showed the
serum anti-FLNC autoantibody level was significantly
higher in low-grade gliomas than in high-grade gliomas or
healthy volunteers (low-grade vs. high-grade: p = 0.0101,
low-grade vs. healthy: p < 0.0001) (Figure 3-a). We then an-
alyzed the antibody level in a prospectively-collected valid-
ation set consisting of 66 glioma patients (low-grade, 37;
high-grade, 29) and 39 healthy volunteers (Table 1). The
significantly increased autoantibody level was confirmed in
the patients with low-grade gliomas as compared to those
in high-grade tumors or healthy volunteers (low-grade vs.
high-grade: p = 0.0036, low-grade vs. healthy: p = 0.0010)
(Figure 3-b). Although the categorization of grade I and
grade II gliomas into low-grade gliomas is generally used in
the clinical setting, these two are different diseases bio-
logically and clinically. So, the anti-FLNC autoantibody
Table 3 Sensitivity and specificity of anti-FLNC antibody
n Positive Negative
(absorbance ≥0.31) (absorbance<0.31)
Low-grade gliomas 72 52 20
Healthy volunteers 77 15 62
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showed that those of grade I and grade II, and also of
grade III and grade IV, were at the same levels (Table 2).
To know whether the increase in anti-FLNC auto-
antibody levels is specific to low-grade gliomas, the pa-
tients with other brain lesions whose MRI manifests a
hypointesity on T1-weighted image and hyperintensity on
T2-weighted image were examined. The anti-FLNC auto-
antibody levels for meningioma and cerebral infarction
were at the same level of healthy volunteers (p = 0.2281,A
B
Figure 4 Serum anti-FLNC autoantibody levels and glioma progressio
serum anti-FLNC autoantibody concentrations (p = 0.0094, R = −0.433). (B) S
large tumors (size ≥3 cm) and small tumors (size <3 cm).and p = 0.5581, respectively) (Table 2). The ROC curve
analysis showed that a cutoff value of 0.31 provided the
best sensitivity and specificity for the differential diagnosis
between patients with low-grade gliomas and healthy vol-
unteers. By using this cutoff value, the anti-FLNC auto-
antibody biomarker system correctly classified 52
(sensitivity; 72.2%) of 72 low-grade glioma patients and 62
(specificity; 80.5%) of 77 healthy volunteers (Table 3). Al-
though the diagnostic ability was not sufficient for clinical
application, the autoantibody-based tumor markers de-
tected in the patients’ sera may contribute to the construc-
tion of early diagnosis system for low-grade gliomas.
The filamin C mRNA expression level inversely corre-
lated with the serum anti-FLNC autoantibody concentra-
tions (p = 0.0094) (Figure 4-a). The serum anti-FLNC
autoantibody levels showed no difference between large
tumors (size ≥3 cm) and small tumors (size <3 cm)n. (A) Filamin C mRNA expression level inversely correlated with the
erum anti-FLNC autoantibody levels were not difference between
AB
C
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ing anti-FLNC autoantibody is induced at the early stage
of glioma progression, and the serum level decreases with
tumor progression.
There was a discrepancy between the decreased level of
anti-FLNC autoantibody and the increased tissue expres-
sion of FLNC in the patients with high-grade gliomas. To
investigate the mechanisms for the decreased level of anti-
FLNC autoantibodies in high-grade glioma patients in
spite of the high tissue expression, we first measured per-
ipheral blood lymphocyte amount, which showed that the
mean lymphocyte ratio in the peripheral blood of grade II
glioma patients was equivalent level as healthy volunteers,
but those in grade III and grade IV glioma patients were
significantly decreased compared with healthy volunteers
(both p < 0.0001) (Figure 5). The lymphocytopenia would
contribute to the decreased anti-FLNC autoantibody level
in high-grade glioma patients. Then, serum FLNC protein
concentration levels were measured utilizing the sandwich
ELISA to be proved equivalent among low-grade gliomas,
high-grade gliomas and normal volunteers (Figure 6-a).
Serum levels of total IgG and anti-GST autoantibody were
also not different among the patient groups and normal
volunteers (Figure 6-b and 6-c), which indicated that gen-
eral B cell function was maintained and that the decreased
level of anti-FLNC autoantibody production was not a
non-specific reaction but was specific for FLNC.
All the glioma patients included in this study were also
subjected to survival analysis. Figure 7-a shows Kaplan-
Meier overall survival curves for the two patients groups
divided by the anti-FLNC antibody level of 0.31 in the
ELISA. The group presenting higher anti-FLNC auto-
antibody levels achieved significantly longer survival pe-
riods (p < 0.01). When the survival analysis was focusedFigure 5 The mean lymphocyte ratio in the peripheral blood of
grade II glioma patients was equivalent as healthy volunteers,
but those in grade III and grade IV glioma patients were
significantly decreased compared with healthy volunteers
(both p < 0.0001).
Figure 6 Non-specific factors affecting serum autoantibody
levels. (A) Serum FLNC protein concentration levels were measured
utilizing the sandwich ELISA to be proved equivalent among low-grade
gliomas, high-grade gliomas and normal volunteers. (B) Serum total IgG
and (C) ant-GST autoantibody levels were not different among low-
grade gliom patients, high-grade glioma patients and normal volunteers.on low-grade gliomas, the patients with higher anti-
FLNC autontibody level (≥0.31) lived significantly longer
than those with lower levels (Figure 7-b). Likewise in
high-grade gliomas, the patients with higher antibody level
had significantly longer survival periods (Figure 7-c).
Serum anti-FLNC autoantibody is a useful predictor for
longer survival periods in patients with both low-grade gli-
omas and high-grade gliomas.
Discussion
The present study showed that FLNC protein expression
increased according to tumor histological grade in glioma
and the circulating anti-FLNC autoantibody was induced
AB
C
Figure 7 Correlations of serum anti-FLNC autoantibody
concentration measured by ELISA and survival of glioma
patients. Kaplan-Meier survival curves of glioma patients show that a
group having higher values of serum anti-FLNC autoantibody (≥0.31)
survived significantly longer than the other group with lower values
(A) in all glioma patients (p = 0.0040), (B) in low-grade glioma patients
(p = 0.0070), (C) and in high-grade glioma patients (p = 0.0310).
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sion. In spite of the immunological privileged nature of the
brain, the aberrant FLNC production could induce immune
reaction. The induced serum autoantibody level decreased
in high-grade gliomas or in a late stage of tumor progres-
sion. The patients who had induced strong immune reac-
tion with high level of circulating anti-FLNC autoantibody
survived longer than those with weak immune reaction.
Antitumor immune responses against glioma antigensefficiently worked as immune-surveillance system in the
early stage of gliomagenesis. These results collectively pro-
vide an evidence that serum anti-FLNC autoantibody can
be a potential serum biomarker for early diagnosis of low-
grade gliomas. However, a large-scale prospective study is
required to confirm the usefulness of autoantibody- based
biomarkers for gliomas.
Filamins are large cytoplasmic proteins whose dimers
provide cells with mechanical resilience by cross-linking
the actin filaments into dynamic three-dimensional struc-
tures [11-14]. Filamin A and B are ubiquitous, whereas
FLNC is a muscle-restricted isoform. However, FLNC
abundantly exists in both fetal brains and spinal cords
[11,12]. Since many signaling molecules and receptors
bind to the C-terminal region of filamins, it is now becom-
ing clear that filamin is not merely a cytoskeletal support
protein, but an important bridge between architecture and
intracellular molecular signaling [23]. The C-terminal half
of filamin A is reported to be a docking site for many
intracellular signaling molecules, such as RalA, Rac, Rho,
and Cdc42, and membrane receptors [24,25]. FLNC also
binds some trans-membrane proteins such as sarcoglycan,
presenilin, caveolin-1, and β1 integrin [26-29]. Recruit-
ment of these signaling molecules to the C-terminal re-
gion of filamin facilitates their functional communication
[23]. All these molecular hub function of filamins contrib-
utes to cancer progression, including metastasis and DNA
damage response [15-22,30].
Actually, serum autoantibodies against filamins were re-
ported to be detected in several cancers including colon
and breast cancers [22]. In contrast, the central nervous
system (CNS) is known to be an immunological privileged
site and it was believed that antibody responses are only
rarely elicited by the broad spectrum of antigens expressed
by glioma [31]. We have shown that immune responses ef-
fectively operate even for intracerebral antigens when the
tumor was in an early stage. The antibody response was
gradually suppressed as tumor malignancy progressed. Not
the inherent immune privilege of the CNS but the acquired
immunosuppressive effect in glioma progression was the
main cause of the suppressed FLNC antibody response in
high-grade gliomas. However, the precise mechanism of
the discrepancy between the higher tissue expression of
FLNC in high-grade gliomas and the lower serum antibody
level in these patients remained to be known. Local im-
munosuppression induced by T-cell specific lymphocytepe-
nia is well documented in high-grade gliomas [31]. The
impaired immunity is first occurred by immunosuppressive
factors secreted by the tumors, such as vascular endothelial
growth factor (VEGF), interleuikin-10 (IL-10), transform-
ing growth factor-β (TGF-β), prostaglandin E2 (PGE2). Af-
fected monocytes make a shift in cytokine secretion to
favor a decrease in Th1-type cytokines and increase in
Th2-type cytokines to induce T-cell signaling defect, IL-2
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(NK) cell activity depression [31-33]. The long-term anti-
gen exposure from a large tumor could induce immune
tolerance through development of immune resistant tumor
variants and the tumor microenvironment inducing im-
mune cell anergy or death [34-36]. The induction and sup-
pression of circulating anti-FLNC autoantibody would be
individually regulated by the complex interaction between
the host immune system and the tumor biology.
Conclusion
In conclusion, we identified a novel glioma antigen, FLNC,
utilizing SEREX and found that its autoantibody level is el-
evated in low-grade glioma patients compared with nor-
mal volunteers and high-grade glioma patients. Serum
anti-FLNC autoantibody is thereby indicated to be a novel
serum marker for the early diagnosis of low-grade gliomas.
The conclusions of this study are limited by the small
sample size and should be confirmed in a larger prospect-
ive study with an independent cohort of patients.Additional file
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